Scientific misconduct, the pharmaceutical industry, and the tragedy of institutions

Medicine and Law

Volumn 26, Issue 3, 2007, Pages 431-446

  Cohen Kohler, Jillian Clare ^a   Esmail, Laura C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Business ethics; Drug industry; Ethics; Pharmaceutical ethics; Pharmaceuticals; Scientific misconduct

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; GABAPENTIN; PAROXETINE; PLACEBO; ROFECOXIB; ROSIGLITAZONE; TROVAFLOXACIN; ZIDOVUDINE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG FATALITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS ABUSE; INDUSTRIALIZATION; INFORMED CONSENT; INTERNATIONAL COOPERATION; MAJOR DEPRESSION; MEDICAL ETHICS; MENINGITIS; MONOTHERAPY; POLICY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PROFIT; RESEARCH SUBJECT; SCIENTIFIC MISCONDUCT; SEIZURE; STANDARDIZATION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION;

CANADA; CODES OF ETHICS; DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; ORGANIZATIONAL POLICY; SCIENTIFIC MISCONDUCT; SOCIAL RESPONSIBILITY;

EID: 35448939678     PISSN: 07231393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Cohen JC, Illingworth P, Schuklenk U. The Power of Pills: Social, Ethical, and Legal Issues in Drug Development, Marketing, and Pricing. London: Pluto Press; 2006.
2. Nylenna M, Simonsen S. 2006. Vol 367. The Lancet. "Scientific misconduct: A new approach to prevention."
3. World Health Organization. WHO Medicines Strategy Countries at the Core 2004-2007. Geneva: World Health Organization; 2004: 5.
4. Avorn J. Evaluating drug effects in the post-Vioxx world: There must be a better way. Circulation 2006;113:2173-6.
5. Wilde-Mathews A, Martinez B. E-Mails Suggest Merck Knew Vioxx's Dangers at Early Stage. The Wall Street Journal. 2004 Nov 1; Sect. A:1.
6. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364:1995-6.
7. Topol EJ. Failing the public health: Rofecoxib, merck, and the FDA. N Engl J Med. 2004;35:1707-9.
8. Hawthorne F. Inside the FDA: 7he Business and Politics Behind the Drugs We Take and the Food We Eat. New Jersey: John Wiley & Sons Inc; 2005.
9. Institute of Medicine. The Future of Drug Safety: Action Steps for Congress. Sept 2006. Available from: http://www.iom.edu/CMS/ 3733.aspx (Accessed Mar 21, 2007].
10. Curfman GD, Morrisey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis," N Engl J Med 2000;343:1520-8.
11. Curfman GD, Morrisey S, Drazen JM. N Engl J Med 2005;353:2813-4.
12. Armstrong D. Bitter Pill: How the New England Journal Missed Warning Signs on Vioxx. The Wall Street Journal. 2006 May 15;Sect. A:1.
13. The People of the State of New York, by Eliot Spitzer, Attorney General of the State of New York against Glaxosmithkline, plc., Smithkline Beecham Corporation. (June 2, 2004). Available from: http://www.oag.state.ny.us/press/2004/jun/jun2b_04_attach1.pdf [Accessed Mar 27, 2005].
14. Office of New York State Attorney General Eliot Spitzer. Major Pharmaceutical Firm Concealed Drug Information [press release on the Internet]. 2004 June 2. Available from: http://www.oag.state.ny.us/ press/2004/jun/jun2b_04.html [Accessed Mar 27, 2005].
15. Silverman E. Sales reps told not to divulge Paxil data. The NJ Star Ledger. 2004 Sep 29. Available from: http://www.ahrp.org/infomail/ 04/09/30.php (Accessed Mar 27, 2005].
16. US Food and Drug Administration, Center for Drug Evaluation and Research [homepage on the Internet]. Questions and Answers on Paxil (paroxetine hydrochloride); [created 2003 Jun 19]. Available from: http://www.fda.gov/cder/drug/infopage/paroxetine/paxilO&A.htm [Accessed May 27, 2006].
17. United States District Court, Southern District of New York. The People of the State of New York by Eliot Spitzer, Attorney General of the State of New York (Plaintiff), against, GlaxoSmithKline PLC, d/b/a GlaxoSmithKline, Smithkline Beecham Corporation, c/b/a GlaxoSmithKline (Defendant). Civil Action No. 04-CV-5304 MGC. Consent Order and Judgment. Available from: http://www.oag.state.ny.us/press/2004/aug/ aug26a_04_attach1.pdf [Accessed June 2, 2007].
18. Meier B. For drug makers, a downside to fall disclosure. The New York Times. 2007 May 23. Available from: http://www.nytimes.com/2007/ 05/23/business/23drug.html?ex=1180929600&en=64c1829b668cf799&ei= 5070 [Accessed June 2, 2007].
19. Lemmens T. Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene. J Law Med Ethics. 2004;Winter:2-18.
20. Steneck NH. Fostering Integrity in Research: Definitions, Current Knowlegde, and Future Directions. Sci Eng Ethics. 2006;12:53-74.
21. Hyder AA et al. Ethical review of health research: A perspective from developing country researchers. J Med Ethics. 2004;30:68-72.
22. Angell M. The truth about the Drug Companies: How They Deceive Us and What To Do About it. New York: Random House;2004.
23. IGATE Clinical Research Internatiol [hompage on the internet]. About Us. Available from: http//www.igatecorp.com/icri/html/aboutus/tia.htm [Accessed Mar 30, 2005].
24. Bodenheimer T. Uneasy alliance: Clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:1539-44.
25. Ahmad K. Drug company sued over research trial in Nigeria. Lancet. 2001;358:815.
26. Hensley S. Court revives suit against Pfizer on Nigeria Study. The Wall Street Journal. 2003 Oct 13. Available from: http://www.drugawareness.org/Archives/4thQtr_2003/record0041.html [Accessed Mar 30, 2005].
27. Stephens J. Panel faults Pfizer in '96 clinical trial in Nigeria: unapproved drug tested on children. The Washington Post. 2006 May 7; Sect. A:01.
28. McGreal C. Nigeria sues Pfizer for $7bn over 'illegal' tests on children. The Guardian. 2007 June 5. Available from: http://www.guardian.co.uk/medicine/story/0..2095955.00.html [Accessed 6 June 2007].
29. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the Human Immunodeficiency Virus in developing countries. N Engl J Med. 1997;337:853-6.
30. Angell M. The ethics of clinical research in the third world. N Engl J Med. 1997;337:847-9.
31. John F. Kennedy School of Government Case Program, Harvard University. The debate over clinical trials of AZT to prevent mother-to-infant transmission of HIV in developing nations. C14-99-1535.9. Available from: http://www.ksg.harvard.edu/case/azt/ethics/home.html [Accessed June 2, 2007].
32. Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med 1997;337:1003-5.
33. Benatar SR, Singer PA. A new look at international research ethics. BMJ 2000;321:824-6.
34. Macklin R. After Helsinki: Unresolved issues in international research, Kennedy Institute of Ethics Journal, 2001;11:17-36.
35. The World Medical Association. Policy: World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. Available from: http.//www.wma.net/e/policy/ b3.htm [Accessed June 2, 2007].
36. Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva 2002. Available from: http://www.cioms.ch/ frame_guidelines_nov_2002.htm [Accessed June 2, 2007].
37. Benatar SR. Towards progress in resolving dilemmas in intemational research ethics. Journal of Law, Medicines and Ethics. 2004;Winter:574-82.
38. Nair VM, Martin DK. Concerns about ethical review of health research in India. Indian J Med Ethics. 2004;1:119-20.
39. Committee on Oversight and Government Reform. Chairman Henry A. Waxman, 110th Congress. Prescription for Harm: The Decline in FDA Enforcement Activity. (June 26, 2006). Available from: http://oversight.house.gov/ story.asp?ID=I074&lssue=Prescription+Drugs [Accessed Mar 22, 2007]
40. Wazana A. Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? JAMA 2000;283:373-80.
41. Elliot C. The Drug Pushers. The Atlantic Monthly. 2006;297:5.
42. US Department of Justice [homepage on the Internet]. Warner-Lambert to pay $430 million to resolve criminal and civil health care liability relating to off-label promotion [press release]. The Office of Public Affairs Press Room [2004 May 131]. Available from: http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm [Accessed Mar 27, 2005].
43. Bal A. Can the medical profession and the pharmaceutical industry work ethically for better health care? Indian Journal of Medical Ethics. 2004;1:17.
44. Gulhati C. Marketing of medicines in India. BMJ. 2004;328:778-9.
45. Menkes DB. Hazardous drugs in developing countries: The market may be healthier than the people. BMJ. 1997;315:1557-8.
46. Gopalakrishnana S, Murali R. India: Campaign to tackle unethical promotion. WHO Essential Drugs Monitor. 2002;31:22.
47. Drug Promotion Database [homepage on the Internet]. Geneva: World Health Organization Department of Essential Drugs & Medicines Policy; c2002. Why was the Database Developed? Available from: http://www.drugpromo.info/about.asp [Accessed May 27, 2006].
48. Katz D, Caplan AL, Merz JF. All Gifts Large and Small: Towards an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving. American Journal of Bioethics. 2003;3:39-46.
49. Canada's Research-based Pharmaceutical Companies [homepage on the Internet]. Code of Marketing Practices [updated 2005 Jan]. Available from: http://www.canadapharma.org/Industry_Publications/Code/ code_e05Jan.html [Accessed Mar 15, 2005].
50. UN Subcommission on the Promotion and Protection of Human Rights, E/CN.4/ Sub.2/2003/12/Rev.2. Minnesota: University of Minnesota Human Rights Library; c1995-2004 [updated 2005 Oct 30]. Available from: http://www1.umn.edu/humanrts/links/normsAug2003.html [Accessed Mar 28, 2005].
51. Paine E. The Road to the Global Compact: Corporate Power and the Battle Over Global Public Policy at the United Nations. Global Policy Forum, October 2000. Available from: http://www.globalpolicy./reform/papers/ 2000/road.htm#1 [Accessed May 27, 2006].
52. The Global Compact [homepage on the Internet]. New York: United Nations; [updated 2005 May 17]. The Ten Principles. Available from: http://www.unglobalcompact.org/AboutTheGC/TheTenPrinciples/ index.html [Accessed May 27, 2006].